A carregar...
A phase I–II evaluation of veliparib (NSC#737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: An NRG Oncology/Gynecologic Oncology Group study
PURPOSE: To evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim or pegfilgrastim neutrophil support in women with persistent or recurrent uterine cervix cancer. EXPERIMENTAL DESIGN: This phase...
Na minha lista:
| Publicado no: | Int J Gynecol Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4336206/ https://ncbi.nlm.nih.gov/pubmed/25594147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000380 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|